NCT07506369Recruiting
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 24 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Obesity
- NCT number
- NCT07506369
What you commit to
- Study type: Interventional
- Planned participants: 18
- From 1 Apr 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery)
- Previous pancreatic disease and/or neoplasia
- Initiation of special diets, lifestyle changes and/or weight loss \>5% of total body weight within three months prior to or during study period
Other illness
- History of hepatobiliary and/or gastrointestinal disorder(s)
- Kidney disease
- Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation
Lab values
- Anaemia (haemoglobin below normal range)
- Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment
Other
- Regular tobacco smoking and/or use of other nicotine products
Who the study is looking for
- Male
- Age between 18 and 65 years at the time of inclusion
- Body mass index 18-27 kg/m2
- Fat percentage \< 20%
- Informed oral and written consent
Age in the registry: 18 years to 65 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Clinical Metabolic Research, Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.